Better testing
technology

Better testing
technology

Better testing
technology

Better testing
technology

About Anora

Anora uses chromosomal microarray analysis featuring single nucleotide polymorphism (SNP) technology. Combined with Parental Support™ technology, Anora provides more comprehensive results across all chromosomes than standard karyotyping and array comparative genomic hybridization (CGH). 

Conditions screened

Anora is clinically validated to detect whole chromosome aneuploidy, triploidy, tetraploidy, uniparental disomy, and deletions and duplications greater than 5 Mb. Terminal deletions or duplications and clinically significant deletions and duplications down to 1 Mb are also reported.

 

The Anora difference

 

  • Approximately one week turnaround time, allowing for faster follow-up care
  • No cell culture needed; less than 1% chance of test failure
  • Higher detection rates than all other products of conception (POC) tests on the market
  • Reports only clinically significant deletions and duplications, with clear follow-up recommendations
  • Able to determine parent of origin for most chromosome abnormalities

 

  • Detection of maternal cell contamination with a single test
  • Identifies chromosome abnormalities associated with increased risk of gestational trophoblastic disease (GTD) (complete paternal UPD and triploidy of paternal origin)
  • Paraffin POC testing can be performed for previous losses
  • Only a small (pea-sized) amount of tissue required

The Anora difference

 

  • Approximately one week turnaround time, allowing for faster follow-up care
  • No cell culture needed; less than 1% chance of test failure
  • Higher detection rates than all other products of conception (POC) tests on the market
  • Reports only clinically significant deletions and duplications, with clear follow-up recommendations
  • Able to determine parent of origin for most chromosome abnormalities

 

  • Detection of maternal cell contamination with a single test
  • Identifies chromosome abnormalities associated with increased risk of gestational trophoblastic disease (GTD) (complete paternal UPD and triploidy of paternal origin)
  • Paraffin POC testing can be performed for previous losses
  • Only a small (pea-sized) amount of tissue required

The Anora difference

 

  • Approximately one week turnaround time, allowing for faster follow-up care
  • No cell culture needed; less than 1% chance of test failure
  • Higher detection rates than all other products of conception (POC) tests on the market
  • Reports only clinically significant deletions and duplications, with clear follow-up recommendations
  • Able to determine parent of origin for most chromosome abnormalities

 

  • Detection of maternal cell contamination with a single test
  • Identifies chromosome abnormalities associated with increased risk of gestational trophoblastic disease (GTD) (complete paternal UPD and triploidy of paternal origin)
  • Paraffin POC testing can be performed for previous losses
  • Only a small (pea-sized) amount of tissue required

The Anora difference

 

  • Approximately one week turnaround time, allowing for faster follow-up care
  • No cell culture needed; less than 1% chance of test failure
  • Higher detection rates than all other products of conception (POC) tests on the market
  • Reports only clinically significant deletions and duplications, with clear follow-up recommendations
  • Able to determine parent of origin for most chromosome abnormalities

 

  • Detection of maternal cell contamination with a single test
  • Identifies chromosome abnormalities associated with increased risk of gestational trophoblastic disease (GTD) (complete paternal UPD and triploidy of paternal origin)
  • Paraffin POC testing can be performed for previous losses
  • Only a small (pea-sized) amount of tissue required

Faster results, improved accuracy 

Anora testing has advantages over standard karyotyping. Only Anora miscarriage testing uses a SNP microarray combined with Parental Support technology to give highly accurate results. Since no cell culture is needed, the chance of test failure is less than 1% and results can be returned within five business days. With Anora testing, a sample of the mother’s blood is requested for comparison to the miscarriage tissue sample. This enables the lab to determine whether a normal female chromosome result is truly fetal or due to maternal cell contamination. Published literature shows that without this maternal testing, over half of "normal female" results are actually results of testing the mother, not the pregnancy that was miscarried. In standard karyotyping, there is no way to differentiate a normal female result as fetal or maternal in origin.

Traditional chromosome analysis, often called a "karyotype," requires growing cells in the laboratory (cell culture). This process takes up to a month and is not always successful. Up to 25% of the time, cell culture fails, leading to no test results. 

Distinguish between maternal and fetal DNA

Anora identifies maternal cell contamination (MCC) by using a maternal blood sample or buccal swab to distinguish between fetal and maternal DNA. Properly identifying fetal versus maternal DNA avoids not knowing if a normal female result is fetal or due to MCC. Some studies have found that more than half of miscarriage samples showing a result of normal female chromosomes were the result of MCC.

 

Identify the origin of molar pregnancy

Molar pregnancies can carry serious risks to the mother, including a type of cancer called gestational trophoblastic disease (GTD). The detection of a molar pregnancy is crucial to your patient’s clinical management. Full paternal UPD and triploidy of paternal origin carry a risk of molar pregnancy for your patient. 

Anora is the only miscarriage test that identifies the parental origin of triploidy. This is important because triploidy of maternal origin is not a cause of a molar pregnancy and does not put a woman at risk for GTD.

 

Learn More

Back to Top